Loading clinical trials...
Loading clinical trials...
Single and Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAY 3283142 Given as Immediate Release (IR) Tablets in Chinese Healthy Participants in a Randomized, Placebo-controlled, Single-blind, Group-comparison Design
Conditions
Interventions
BAY3283142
Placebo
Locations
1
China
The First Affiliated Hospital of Guangzhou University of TCM
Guangzhou, Guangdong, China
Start Date
July 4, 2024
Primary Completion Date
September 19, 2024
Completion Date
September 19, 2024
Last Updated
September 24, 2024
NCT05398783
NCT00104325
NCT07547098
NCT07118891
NCT01399385
NCT07295717
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions